RaQualia Pharma (TSE:4579) Beta: -0.1796 (As of Jul. 08, 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
57 GF Score
Price 円468.00
GF Value 円961.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Beta?

RaQualia Pharma TSE:4579 -2.70% 57 Beta is -0.1796 as of Jul. 08, 2026. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-08), RaQualia Pharma's Beta is -0.1796.


RaQualia Pharma  (TSE:4579) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


RaQualia Pharma Beta Related Terms


RaQualia Pharma Beta Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Beta Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 1.26 0.98 0.59 -0.36

RaQualia Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.38 0.58 -0.36 0.05

TSE:4579 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, RaQualia Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Beta distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's Beta falls into.


TSE:4579
57GF Score
RaQualia Pharma Inc TSE:4579
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.1796 mean?
RaQualia Pharma (TSE:4579) has a Beta of -0.1796 as of Jul. 08, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for RaQualia Pharma and its competitors.
Is RaQualia Pharma's Beta too high?
RaQualia Pharma's current Beta is -0.1796. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Beta compare to VRTX and REGN?
RaQualia Pharma's Beta of -0.1796 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for RaQualia Pharma and its competitors. RaQualia Pharma's current Beta is -0.1796. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Beta is -0.1796. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Beta is -0.1796 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Beta: -0.1796
  • GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score

Get the complete analysis for TSE:4579

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price
円961.31
GF Value